Clinical Trials Browser

Observational × Neoplasm, Residual × Thoracic × Clear all

Breast Neoplasms, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Melanoma, Neoplasms, Unknown Primary, Urogenital Neoplasms, Neoplasm, Residual

NCT07291921 2026-03-03

To Conduct Multi-omics Integrated Studies in Peripheral Blood, Such as Fragment Omics, Metabolomics and Epigenetics, and Establish Non-invasive Dynamic Follow-up Monitoring Programs During Perioperative and Postoperative Periods (Observational Study)

Recruiting

100 enrolled

Thoracic

Lung Neoplasms, Neoplasm, Residual

NCT06963307 2025-05-09

LumenDx

Recruiting

300 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm, Residual

NCT06111807 2025-03-30

MRD-LUNG

Recruiting

248 enrolled

Thoracic

Pathologic Complete Response, Hypersensitivity, Lung Neoplasms, Neoplasm, Residual

NCT06854939 2025-03-03

MRDSEEKER

Not yet recruiting

350 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm, Residual

NCT06514118 2024-07-23

Chemoimmunotherapy Plus Residual Lesion Irradiation for the Treatment of Extensive Stage Small-cell Lung Cancer

Recruiting

70 enrolled

Thoracic

Neoplasm, Residual, Small Cell Lung Carcinoma

NCT05219734 2024-03-12

MARIA

Active not recruiting

400 enrolled

GastrointestinalGenitourinaryThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Neoplasms, Colorectal Neoplasms, Neoplasm, Residual

NCT06198868 2024-01-12

MRD-guided Prognosis Prediction and Adjuvant Treatment Based on CTC and ctDNA in NSCLC

Recruiting

60 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm, Residual

NCT05637580 2022-12-05

Pathological Tumor and Lymph Node Responses After Neoadjuvant Immunochemotherapy in Initially-unresectable NSCLC

Completed

110 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm, Residual

NCT05167604 2021-12-22

Clinical Value of MRD Monitoring for Adjuvant Therapy in Postoperative NSCLC

Unknown

150 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm, Residual

Clinical Trials

SHERLOCK

To Conduct Multi-omics Integrated Studies in Peripheral Blood, Such as Fragment Omics, Metabolomics and Epigenetics, and Establish Non-invasive Dynamic Follow-up Monitoring Programs During Perioperative and Postoperative Periods (Observational Study)

LumenDx

MRD-LUNG

MRDSEEKER

Chemoimmunotherapy Plus Residual Lesion Irradiation for the Treatment of Extensive Stage Small-cell Lung Cancer

MARIA

MRD-guided Prognosis Prediction and Adjuvant Treatment Based on CTC and ctDNA in NSCLC

Pathological Tumor and Lymph Node Responses After Neoadjuvant Immunochemotherapy in Initially-unresectable NSCLC

Clinical Value of MRD Monitoring for Adjuvant Therapy in Postoperative NSCLC